Non-clinical safety studies for biotechnologically-derived pharmaceuticals: conclusions from an International Workshop

Non-clinical Safety Testing of Products of Biotechnology: Issues of Concern. Griffiths SA , Ashton GA and Lumley CE. CMR International Report, CMR95-63R, December 1995.

Safety Evaluation of Biotechnologically-derived pharmaceuticals: Facilitating a Scientific Approach. (eds) Griffiths SA and Lumley CE. Kluwer Academic Publishers: The Netherlands , 1997. ISBN 0-7923-8732-5.

Mannering GJ , DeLoria LB. The pharmacology and toxicology of the interferons; an overview . Annual Review of Pharmacology and Toxicology 1986; 26: 455-515 .

Hayes TJ , Cavagnaro JA. Progress and challenges in the preclinical assessment of cytokines . Toxicology Letters 1992; 64/65: 291-297 .

Siegel JP et al Development of biological therapies for oncologic use. In: Biologic Therapy of Cancer 1995; 2nd ed (eds) DeVita VT , Hellman S and Rosenberg SA , JB Lippincott Company , pp 879-890.

Ryffel B. Cytokine induced pathology. International Review of Experimental Pathology 1993; 34 A-34 B.

Sreevalasan T. Biologic therapy with interferon-alpha and beta: preclinical studies. In: Biologic Therapy of Cancer. 1995; 2nd ed, (eds) Devita VT, Hellman S and Rosenberg SA, JB Lippincott Company , pp 347-364.

Tushinski RJ , Mule JJ. Biology of cytokines: the interleukins. In: Biologic Therapy of Cancer. 1995; 2nd ed, (eds) DeVita VT, Hellman S and Rosenberg SA, JB Lippincott Company , pp 87-102.

Hayes TJ , Ryffel B. Safety considerations for recombinant protein therapy: introductory comments . Clinical Immunology and Immunopathology 1997; 83: 1-4 .

Anderson TD , Arceco R , Hayes TJ. Comparative toxicity and pathology associated with administration of recombinant HuIL-1 alpha to animals . International Review of Experimental Pathology 1993; 34(A): 9-36 .

Anderson TD et al. Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals . International Review of Experimental Pathology 1993; 34A: 57-77 .

Renton KW , Mannering GJ. Depression of hepatic cytochrome P-450 dependent monooxygenase systems with administered interferon inducing agents . Biochemical and Biophysical Research Communications 1976; 73: 343-348 .

Parkinson A et al. Effects of three recombinant human leukocyte interferons on drug metabolism in mice . Drug Metabolism and Disposition 1982; 10 579-585 .

Renton KW , Knuckle LC. Regulation of hepatic cytochrome P-450 during infectious disease . Canadian Journal of Physiology and Pharmacology 1990; 68: 777-781 .

Cribb AE et al. Regulation of cytochrome P-450A and cytochrome P-4502E induction in the rat during the production of interferon alpha/beta . Journal of Pharmacology and Experimental Therapeutics 1994; 268: 487-494 .

Anari MR , Cribb AE , Renton KW. The duration of induction and species influences the downregulation of cytochrome P450 by the interferon inducer polyinosinic acid-polycytidylic acid . Drug Metabolism and Disposition 1995; 23: 536-541 .

Trown PW , Wills RJ , Kamm JJ. The preclinical development of Roferon-A . Cancer 1986; 57: 1648-1656 .

Terrel J , Green JD. Comparative pathology of recombinant murine interferon-gamma in mice and recombinant human interferon-gamma in cynomologous monkeys . International Review of Experimental Pathology 1993; 34B: 73-101 .

Ryffel B. Interleukin-12: role of interferon-gamma in IL-12 adverse effects . Clinical Immunology and Immunopathology 1997; 83: 18-20 .

Hall SS. IL-12 at the crossroads [news] . Science 1995; 268: 1432-1434 .

Lotze M , Gately M. Interleukin-12. Annals of the New York Academy of Sciences . 1996.

Lipani J. Designing non-clinical safety evaluation programmes: The view of the clinician. In: Safety Evaluation of Biotechnologically-derived pharmaceuticals: Facilitating a Scientific Approach. (Eds) Griffiths SA and Lumley CE. Kluwer Academic Publishers: The Netherlands , 1997. ISBN 0-7923-8732-5.